Jakarta, Indonesia — 2022
Villa Medical Center Phuket (www.thailandstemcell.com), a regional pioneer in regenerative medicine logistics, has officially launched GMP-relevant manufacturing for Natural Killer (NK) cell preparation in Indonesia. This landmark initiative enables the annual production and supply of over 500 NK cell preparation kits to support laboratories, hospitals, and ATMP (Advanced Therapy Medicinal Products) research facilities across the country. The initiative represents a critical expansion of immune cell manufacturing in Southeast Asia and underscores Atlantis’ commitment to accelerating access to stem cell and immunotherapy-based treatments.
As a wholly owned subsidiary of Atlantis Bioscience Singapore (www.atlantisbioscience.com), Villa Medical Center Phuket leveraged its group-wide expertise in cellular therapy platforms, reagent development, and cleanroom systems to bring NK cell kit production online in a strategically chosen Indonesian facility. The result is a GMP-aligned, scalable, and locally supported infrastructure capable of fuelling clinical and research progress in NK cell therapy and broader immune-oncology applications.
Meeting the Rising Demand for NK Cell Therapy in Southeast Asia
NK cells, a subset of cytotoxic lymphocytes in the innate immune system, are among the most promising tools in the immunotherapy arsenal. Their unique ability to recognize and destroy tumor cells and virally infected cells without prior sensitization positions them as powerful agents in cancer treatment, infectious disease control, and autoimmune regulation.
Globally, NK cell therapies are advancing through clinical trials for indications including:
- Relapsed leukemia and lymphoma
- Metastatic solid tumors
- Chronic viral infections
- Post-transplant complications
Indonesia, with its growing biotechnology ecosystem and expanding private healthcare sector, is poised to become a central node for clinical research and translational immunotherapy in Southeast Asia. However, until now, domestic access to standardized NK cell kits complete with GMP-grade reagents, media, cytokines, and SOPs has been limited.
Villa Medical Center Phuket identified this critical gap and acted decisively. By establishing a local manufacturing capability, the company not only reduced the cost and delivery time of NK kits but also ensured that the reagents met local regulations while aligning with international ATMP standards.
What’s Inside the Atlantis NK Cell Kit?
Each Atlantis NK cell preparation kit is a complete system for isolating, activating, and expanding NK cells from peripheral blood mononuclear cells (PBMCs) or umbilical cord blood. Designed with flexibility and reproducibility in mind, the kit components include:
- Serum-free expansion media enriched with IL-2 and IL-15
- Feeder-free activation protocols to reduce risk of contamination
- Xeno-free supplements suitable for clinical development
- Flow cytometry-compatible staining and control reagents
- SOPs and QC checklists developed under GMP-relevant conditions
These kits are ideal for research groups, immunotherapy developers, and clinical translation programs focused on generating NK cells for both autologous and allogeneic therapies. They can also be used in combination with stem cell-derived NK platforms, offering a bridge between regenerative medicine and cellular immunotherapy.
GMP-Relevant Production: What It Means and Why It Matters
Although the kits are not manufactured in a full GMP-certified pharmaceutical facility, Villa Medical Center Phuket follows GMP-relevant production standards meaning that all procedures adhere to the core principles of cleanroom handling, batch tracking, sterilization, and validated process controls. This makes the products suitable for early-phase clinical research and for laboratories working toward full GMP-readiness.
Atlantis Bioscience Singapore, the parent company, provided technical support and quality system training to ensure compliance with ASEAN and Indonesian BPOM guidelines. This involved:
- Cleanroom design consulting and process layout
- Documentation templates for SOPs and batch records
- Reagent sterilization and endotoxin testing
- Product traceability for audit and approval processes
This GMP-relevant strategy is especially valuable in Indonesia, where local labs are rapidly scaling up but may not yet have full pharmaceutical-grade manufacturing licenses. By providing “bridge-quality” reagents, Atlantis enables these labs to conduct legitimate preclinical and translational work while maintaining a path to future commercialization.
Empowering Indonesia’s Cell Therapy Ecosystem
This initiative is about more than just supplying kits it’s about empowering a national cell therapy infrastructure. Villa Medical Center Phuket has worked closely with Indonesian academic hospitals, private clinics, and research institutions to support training and technology transfer related to NK cell therapy.
The company provided:
- On-site workshops on cell culture and immune profiling
- Remote support for SOP adaptation and troubleshooting
- Custom formulation services for labs needing personalized media
- Regulatory guidance for product registration under Indonesian laws
By enabling local innovation and reducing dependency on imports, Atlantis is helping Indonesia build sovereign capabilities in stem cell and immune cell processing an important step in building long-term resilience in national healthcare.
A Seamless Extension of Atlantis Bioscience’s Vision
As a subsidiary of Atlantis Bioscience Singapore, Villa Medical Center Phuket embodies the group’s vision of accelerating access to regenerative medicine and next-generation biologics across Asia. Atlantis Bioscience is recognized for its robust portfolio of:
- Stem cell media and serum supplements
- Probiotic research and therapeutic nutrition
- Exosome development platforms
- Reagent and cell banking logistics
- Immunotherapy support systems
By integrating Atlantis Bioscience’s expertise into the NK workflow in Indonesia, the group has created a transnational network capable of supporting ATMP development from Bangkok to Jakarta, and from research labs to the clinic.
Looking Ahead: Toward Clinical Trials and Global Collaboration
The Indonesian NK cell kit program is just the beginning. Villa Medical Center Phuket plans to use this platform to pilot expanded services such as:
- GMP-grade cryopreservation solutions for NK cell banking
- MSC-NK co-culture kits for dual-regenerative and immune modulation
- Clinical trial support packages for hospitals conducting cell therapy studies
- Expanded capacity to meet growing demand in Malaysia, the Philippines, and Vietnam
With these initiatives, Atlantis aims to become a leading provider of stem cell therapy and ATMP-enabling technologies in Southeast Asia, facilitating a regional surge in patient access and translational research.
Conclusion: Strengthening Southeast Asia’s Regenerative and Immune Medicine Infrastructure
The launch of GMP-relevant NK cell kit production in Indonesia positions Villa Medical Center Phuket as a transformative force in Southeast Asia’s biotech sector. By aligning world-class immune therapy tools with local production and education, the company is closing the gap between scientific innovation and real-world medical access.
As NK cell therapy and other ATMPs continue to gain ground globally, initiatives like this will ensure that the benefits are felt not only in leading academic centers but also in the hospitals and communities across Indonesia and its neighbouring nations.
Villa Medical Center Phuket
Villa Sukhothai, Soi Pasak 8, Choeng Thale,
Thalang District, Phuket, Thailand
Email: atlantisphuket@gmail.com
Phone/WhatsApp: +66 99 301 6969